LATEST

• BUSINESS Net Profit at 24 Japan Drug Makers Tops 2 Trillion Yen, Led by Astellas and Sumitomo
  May 25, 2026

• BUSINESS Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
  May 25, 2026

• COMMENTARY Are Technical Discussions Enough for Japan’s CEA System?
  May 25, 2026

• REGULATORY Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
  May 25, 2026

• REGULATORY Ishin Deepens Debate on Healthcare Macroeconomic Indexing
  May 25, 2026

• BUSINESS Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
  May 22, 2026

• BUSINESS Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
  May 22, 2026

• REGULATORY Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
  May 22, 2026

• ORGANIZATION Novartis’ Pullicino to Helm EFPIA Japan from July
  May 22, 2026

• BUSINESS Servier’s Voranigo Seen as Potential Standard of Care for Glioma: Expert
  May 22, 2026

• ORGANIZATION FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
  May 22, 2026

• ORGANIZATION JPMA Exec Urges Broader Debate on Japan’s CEA System
  May 22, 2026

• REGULATORY Blister Pack Supplies Seen Returning to Normal: Health Minister
  May 22, 2026

• BUSINESS Ultragenyx’s LC-FAOD Therapy Dojolvi Now Available in Japan
  May 22, 2026

• BUSINESS SanBio Debuts Akuugo Stem Cell Therapy for Traumatic Brain Injury
  May 22, 2026

• REGULATORY LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
  May 22, 2026

• REGULATORY Oncolys’ Telomelysin Wins Backing from Japan Panel
  May 22, 2026

• BUSINESS BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
  May 21, 2026

• REGULATORY MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
  May 21, 2026

• BUSINESS Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
  May 21, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• …
• Next ›
• 最終 »